A Phase Ib Randomized, Placebo-controlled, Double-blinded Study Evaluating the Safety of Ataciguat (HMR1766) in Patients With Moderate Calcific Aortic Valve Stenosis
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2016
Price : $35 *
At a glance
- Drugs Ataciguat (Primary)
- Indications Aortic valve stenosis
- Focus Adverse reactions
- 05 Jul 2016 Status changed from recruiting to completed.
- 09 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 09 Apr 2014 New source integrated (Mayo Clinic; 13-005387)